Axogen, Inc.

AI-generated fair value estimate for this company.

Method: 10-year, two-stage unlevered FCF DCF starting from TTM revenue $251.17M; Yrs1-5 revenue growth 20% to 15% with FCF margin ramping 5% to 13% (from current 3.4%), Yrs6-10 growth 13% to 5% with margin 14% to 18%, 10% discount rate, 4% terminal growth, plus $91.35M net cash, over 58.67M diluted shares.

Reasoning: AxoGen is a high-growth nerve-repair medtech only just crossing into operating profitability, so a margin-expansion multi-stage DCF captures the operating-leverage story better than a static multiple.